SUPPORT FOR YOU AND YOUR PATIENTS THROUGHOUT THEIR TREATMENT JOURNEY
Videos for HCPs
Mechanism of Disease (MOD) Video
Learn what makes most EGFR exon 20 insertion mutations different.
Resources for HCPs
Amivantamab-vmjw (RYBREVANT®) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Flashcard
See the NCCN Guidelines® recommendations for
amivantamab-vmjw (RYBREVANT®).
RYBREVANT® Dosing and Administration Guide
Comprehensive dosing, dose modification, preparation, and administration details for RYBREVANT®.
Supportive Care Guide for RYBREVANT® Adverse Reactions
A helpful guide to address adverse reactions through proactive supportive care and reactive management.
Testing and Treatment for EGFR Exon 20 Insertion Mutation+ mNSCLC
An overview of the NCCN Guidelines® recommendations for the testing and treatment of mNSCLC with EGFR exon 20 insertion mutations.
Janssen CarePath
Janssen CarePath is your one source for access, affordability, and treatment support for your patients.
Reference Lab Fact Sheet
Biomarker testing guidelines and a list of liquid and tissue NGS test providers.
First-infusion Guide
A guide that focuses on how to manage IRRs during a patient’s first infusion of RYBREVANT® in first-line therapy.
Resources for Patients
RYBREVANT® Prospective Patient Brochure
Getting patients started on their journey with RYBREVANT®.
RYBREVANT® Patient Starter Kit Brochure
Helpful information for patients to manage their treatment.
RYBREVANT® Patient Starter Kit Advocacy Flashcard
Organizations in the mNSCLC community that provide support during treatment.
RYBREVANT® Patient Starter Kit Infusion Schedule Flashcard
An overview to help patients understand and prepare for their infusions during treatment.
RYBREVANT® Patient Starter Kit Treatment Journal
A tool to help patients stay organized, prepare, and reflect during their treatment with RYBREVANT®.
Janssen CarePath
Information on insurance coverage, out-of-pocket costs, and treatment support.
Janssen CarePath Savings Program for RYBREVANT®
Eligible commercially insured patients can save on their out-of-pocket medication costs for RYBREVANT®.
Resources for Access & Affordability
RYBREVANT® Medicare Payment Policy Flashcard
Important information regarding Medicare's payment policy for RYBREVANT®.
Coding & Billing Flashcard
An explanation for office staff about insurance codes and billing.
Specialty Distributor Flashcard
A flashcard on how to order RYBREVANT® for your patients.
Sample Letter of Medical Necessity (LMN)
An editable LMN template to use either with an initial claim or when requesting reconsideration for a denied claim.
Sample Exception Letter
A template exception letter to use when requesting an exception for RYBREVANT®.
AMI, amivantamab; EGFR, epidermal growth factor receptor; HCP, healthcare professional; IRR, infusion-related reactions; KOL, key opinion leader; MOA, mechanism of action; mNSCLC, metastatic non-small cell lung cancer; NCCN, National Comprehensive Cancer Network; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.
Patient Support
Lung Cancer Communities and Organizations
EGFR Resisters
The EGFR Resisters is a group of people living with and/or personally affected by EGFR-positive lung cancer.
egfrcancer.org
Exon 20 Group
Patients and their families are welcome to join the Exon 20 Group. Membership is free of charge.
exon20group.org
1-602-618-0183
The GO2 Foundation for Lung Cancer
Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world’s leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.
go2foundation.org
1-800-298-2436
Lung Cancer Foundation of America (LCFA)
LCFA’s mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.
lcfamerica.org
LUNGevity
LUNGevity is the largest national lung cancer-focused nonprofit. They are committed to changing the outcomes for people with lung cancer through research, education, and support.
lungevity.org
1-844-360-5864
These groups and foundations are not affiliated with Janssen Biotech, Inc. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by Janssen Biotech, Inc., or any groups or foundations referenced herein.
Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF)
The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, nonprofit organization. JJPAF gives eligible patients free prescription medicines donated by Johnson & Johnson companies. Patients may be eligible if they don’t have insurance.
Do you have patients who may need help? They can see if they are eligible and get an application at JJPAF.org or call 800-652-6227 (Monday through Friday, 8:00 AM to 8:00 PM ET).
Explore
Register for Updates
Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.